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EndocytosisRip11 is a Rab11 effector protein that has been shown to be important in controlling the trafﬁcking of several in-
tracellular cargoes, including the fatty acid transporter FAT/CD36, V-ATPase and the glucose transporter GLUT4.
We have previously demonstrated that Rip11 translocates to the plasma membrane in response to insulin and
here we examine the basis of this regulated phenomenon in more detail. We show that Rip11 rapidly recycles
between the cell interior and surface, and that the ability of insulin to increase the appearance of Rip11 at the
cell surface involves an inhibition of Rip11 internalisation from the plasma membrane. By contrast the hormone
has no effect on the rate of Rip11 translocation towards the plasma membrane. The ability of insulin to inhibit
Rip11 internalisation requires dynamin and class I PI3-kinases, but is independent of the activation of the protein
kinase Akt; characteristics which are very similar to themechanism bywhich insulin inhibits GLUT4 endocytosis.
© 2015 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The Rab family of small GTPases controls a multitude of trafﬁcking
pathways in eukaryotic cells [1,2]. They cycle between an inactive GDP-
bound state and an active GTP-bound state, in which they interact with
different specialised protein partners that can dictate their subcellular
localisation or even direct their function(s) [3]. Among the Rab protein
family, several Rabs have been shown to regulate trafﬁcking steps of the
endosomal pathway. For instance, Rab5 and Rab7 are involved in the
endocytic trafﬁcking of cargoes and sorting through the early-to-late
endosomes and lysosomes [4–6], Rab4 is involved in the direct recycling
of the transferrin receptor (TfnR) from the early/sorting endosome [7],
and Rab11 is involved in its indirect recycling from the juxtanuclear
recycling compartment back to the plasma membrane [8].
Several Rab11-interacting proteins have been identiﬁed on the basis
of the presence of a conserved Rab11-binding domain (RBD) [9–12].
This family of proteins has been termed the Rab11 family of interacting
proteins (Rab11–FIPs). Among this family, the class I Rab11–FIPs consist
of Rab11–FIP1C (RCP, Rab coupling protein), Rab11–FIP2, and Rab11–des maladies Métaboliques et
Cedex 4, France.
en access article under the CC BY licFIP5 (Gaf1, pp75 or Rip11 as used in this study). They are predomi-
nantly localised to the endosomal recycling compartment, and are
characterised by the presence of an N-terminal C2 domain and a C-
terminal coiled-coil region encompassing the RBD. It has been shown
that this coiled-coil region mediates dimerisation of the Rab11–FIPs
[13], and their N-terminal C2 domain has been shown to bind to
phosphoinositides (PtdIns) [14].
Among the class I Rab11–FIPs, the role of Rip11 in the recycling of
transferrin has been well characterised. There is evidence that Rip11
functions in trafﬁcking from early endosomes to juxtanuclear recycling
endosomes (as suggested in [15]) and in the trafﬁcking of cargo
between the endosomal recycling compartment and the plasma mem-
brane (as suggested in [14,16]). The latter proposal is consistent with
the reported role of Rip11 in the polarised transport of proteins from
apical endosomes to the apical plasma membrane [17], the trafﬁcking
of the fatty acid transporter FAT/CD36 [18], the regulation of insulin
granule exocytosis in pancreatic β-cells [19], the translocation of the
V-ATPase from an intracellular pool to the plasma membrane in
response to acidosis in salivary duct epithelial cells [20] and, as we
have previously demonstrated, the insulin-stimulated trafﬁcking of
the glucose transporter GLUT4 to the plasma membrane of adipocytes
[21].
Rip11 itself translocates from an intracellular compartment(s) to the
plasma membrane in response to insulin and phorbol esters [14,21]. In
response to phorbol esters this translocation requires the presence ofense (http://creativecommons.org/licenses/by/4.0/).
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phosphatidic acid in vitro [14]. Insulin-induced translocation is speciﬁc
to Rip11, as it is not seenwith any of the other class I FIPs [21]. However,
the mechanism(s) by which these stimuli increase the translocation of
Rip11 to the plasma membrane is not yet understood.
We previously reported that the effect of insulin on the translocation
of a GFP–Rip11 chimera to the plasma membrane can be inhibited by
wortmannin, a PI3-kinase inhibitor, and mimicked through over-
expression of a constitutively-active mutant of Akt (Myr–Akt) [21].
This suggests that the phenomenon is PI3-kinase and Akt-dependent,
however wortmannin is an inhibitor of all three classes of PI3-kinases
[22,23] including the Class II and III isoforms that generate phos-
phatidylinositol 3-phosphate on intracellular vesicles. Furthermore,
since our original study was published a highly selective Akt inhibitor,
MK2206 [24] has become available making it easier to explore the
acute regulation of the phenomenon by Akt. The trafﬁckingmechanism
deployed by Rip11 in response to insulin is also not well understood.
Given the previously identiﬁed role of Rip11 in GLUT4 translocation,
together with our observation that Rip11 and GLUT4 colocalise on a
small proportion of intracellular vesicles, we initially reasoned that
Rip11 might translocate to the plasma membrane by ‘piggy-backing’
on GLUT4 vesicles. Thus in this study we examined both the signalling
and trafﬁcking mechanisms involved in more detail.
2. Materials and methods
2.1. Materials
Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were
from Aventi Polar Lipids.
All other materials and reagents were from Sigma unless otherwise
stated. Plasmids encoding mCherry–Rab11 and mCherry–Rab4 were
kindly provided by Peter Cullen (University of Bristol, Bristol, UK).
2.2. Molecular cloning
The mutations in the Rip11 C2 domain were generated by gene
synthesis (Genscript), based on the human sequence of Rip11 (amino
acids 2–221; GenBank accession number AF334812). Codon optimiza-
tion was undertaken essentially to decrease the %GC content and to
facilitate subsequent cloning and site-directed mutagenesis. The wild-
type and R52A/K54A mutant fragments were cloned in frame in the
pGEX3X and peGFP-C1 vectors. To generate the full-length constructs
(i.e. 2–653), the corresponding fragments 2–221 (WT or R52A/K54A)
were excised from the peGFP-C1 using BamHI and subcloned in frame
into the C-terminal part of the Rip11 backbone (219–653) in the
peGFP vector described in [14], generating a GFP–Rip11 2–653 con-
struct. This construct was then excised from the peGFP-C1 vector and
subcloned into the pmCherry-C1 vector to generate mCherry–Rip11.
2.3. Cell culture
3T3–L1 adipocytes were cultured, electroporated and treated as
described before [21]. Stable cell lines were obtained by lentiviral-
mediated transduction of undifferentiated 3T3–L1 by standards
methods as described in [25,26]. Lentiviral plasmids were gifts of
Dr. Giles Cory (University of Exeter, Exeter, UK).
2.4. Live cell imaging and immunoﬂuorescence
For immunoﬂuorescence, cells grown on glass coverslips were treat-
ed as indicated in ﬁgure legends, and ﬁxed with 4% paraformaldehyde
for 20 min. Coverslips were mounted in Mowiol and imaged on a
Leica TCS-SP5 AOBS scanning confocal microscope.
Total internal reﬂection ﬂuorescence (TIRF) microscopy of live cells
was performed at 37 °C on an AM TIRF multi-colour system (Leica)attached to a DMI 6000 inverted epiﬂuorescence microscope (Leica)
using a 100× oil lens (NA = 1.46). The imaging medium consisted of
phenol red-free DMEM/F12 (11,039, Invitrogen). Imageswere captured
using an EM-CCD camera (Hamamatsu) between approx. 2–3 fps at a
penetration depth of 90 nm. EGFP was excited at a wavelength of
488 nm and emission wavelengths were collected between 507 and
543 nm; mCherry was excited at a wavelength of 561 nm and emission
wavelengths were collected between 584 and 616 nm. When required,
cells were treated with 86 nM insulin on themicroscope using a home-
made perfusion system.
For inhibition of endocytosis, 3T3–L1 adipocytes stably expressing
GFP–Rip11 WT were seeded on glass coverslips, and serum-starved
for 3 h. The cells were then treated with vehicle (control), insulin
(87 nM), Mitmab (10 or 40 μΜ) for 20 min at 37 °C. Alexa-Fluor™-
633-transferrin (Invitrogen) was added for 20 min at 37 °C in the
continuous presence of the drugs. The cells were then washed in PBS
and PFA-ﬁxed.
The amount of Rip11 at the cell surfacewas calculated usingVolocity
(PerkinElmer) by manually drawing around individual cells and calcu-
lating the ﬂuorescence intensity from thewhole cell, and then automat-
ically contracting the region of interest by a set number of pixels in
order to exclude the plasma membrane. The intensity within the inner
ring was subtracted from the outer ring to give the amount of Rip11
within the plasma membrane and this value was normalised to total
cellular levels of Rip11 (cell surface/total).
All images used in this manuscript were processed using Photoshop
6.0 (Adobe) and montages generated using Adobe Illustrator (Adobe).
In Fig. 3 the imageswere subjected to contrast enhancement for illustra-
tive purposes only, with all images being processed for display in an
identical manner.
2.5. Recombinant protein puriﬁcation
RecombinantGST-fusion proteinswere produced andpuriﬁed as de-
scribed before [27]. Brieﬂy, Escherichia coli BL21(DE3) (Agilent Technol-
ogies) were transformed by pGEX3X vectors containing the coding
sequence for the Rip11 C2 domain (residues 2–221, WT or PI mutant)
and protein expression was induced by adding 0.4 mM IPTG for 3 h at
30 °C. Bacteria were pelleted by centrifugation, washed with ice-cold
phosphate buffered saline (PBS), and lysed by sonication in buffer
[PBS, 0.4 mM EDTA, 2 mM DTT, 1 mM ATP, 1% Triton X100, 10 U/ml
DNase I, Proteases Inhibitors Cocktail V (Calbiochem)]. The lysate was
clariﬁed by centrifugation at 10,000 g for 10 min at 4 °C, and incubated
with gluthatione-Sepharose beads (GE Healthcare). The beads were
washed extensively in buffer [PBS, 0.4 mM EDTA, 1% Triton X-100]
and then in buffer A [50 mM Hepes pH 7.4, 100 mM NaCl, 1 mM
CaCl2, 1 mMMgCl2]. Recombinant proteins were eluted in buffer A sup-
plemented with 10 mM reduced glutathione.
2.6. Protein–lipid overlay assay
Protein–lipid overlay assay was essentially done as described else-
where [14]. Brieﬂy, PIP Strips™ (Invitrogen — Molecular Probes) were
blocked in buffer A plus 0.1% Tween 20 containing 3% BSA, incubated
overnight at 4 °C with 1.5 μg/ml GST fusion proteins in buffer A plus
0.1% Tween 20 plus 3% BSA and washed extensively. Bound GST recom-
binant proteins were detected using an HRP-coupled anti-GST antibody
(B-14, Santa Cruz Biotechnology Inc).
2.7. Neutral phospholipid binding assay
Neutral phospholipid binding assay was essentially done according
to [16]. Brieﬂy, PC:PE liposomes in a ratio of 80:20 were made by
sonication, incubated in Buffer A +1 mM DTT for 30 min at RT with
recombinant GST or GST–Rip11 C2 domain (WT or PI mutant). After
sedimentation by ultracentrifugation at 70,000 rpm for 10 min at 4 °C
76 F. Boal et al. / Cellular Signalling 28 (2016) 74–82in a TLA-100 Beckman rotor, the supernatants were collected and
the pellets were solubilised in sample buffer, resolved by SDS-PAGE
and the amount of recombinant proteins bound to the lipids
was assessed by Western blotting, using an HRP-coupled anti-GST
antibody.
2.8. Statistical analyses
Unless otherwise stated, all data are provided as a mean ± SEM
from a minimum of three independent experiments. A two-tailed
Student's t-test was used and a ‘p’ value of less than 0.05 taken as indi-
cating a statistically relevant difference.
3. Results
3.1. Insulin stimulates Rip11 translocation to the plasma membrane in a
PI3-kinase-dependent but Akt-independent manner
As exempliﬁed in Fig. 1A (left panel), Rip11 is predominantly local-
ised at intracellular membranes of 3T3–L1 adipocytes in the basalFig. 1. Rip11 translocates to the plasma membrane in a PI 3-kinase dependent but Akt-in-
dependent manner. 3T3–L1 adipocytes stably expressing GFP–Rip11 were serum starved
and stimulatedwith orwithout insulin in the presence of the Akt inhibitorMK2206 or the
PI 3-kinase inhibitor PIK-75, as indicated. (A) Representative confocal images of Rip11
localisation in the presence (right panel) and absence (left panel) of 87 nM insulin. Scale
bar represents 17 μm. (B) Quantiﬁcation of cell surface levels of Rip11 in the absence
and presence of the PI 3-kinase inhibitor, PIK-75 (10 μM), or the Akt inhibitor, MK2206
(10 μM). Results are shown as mean ± SEM (N = 3, with at least 20 cells per condition
(n), *p b 0.05, **p b 0.01,***p b 0.001 t-test). (C) Immunoblots are shownof 3T3–L1 lysates
stably expressing GFP–Rip11 blotted with anti-pAKT (S473) and α-Tubulin (loading con-
trol) antibodies, having been treated under the same conditions as the cells in panel (B).state but translocates to the plasma membrane in response to insulin.
Quantiﬁcation of the images shows that approx. 20% of Rip11 is found
at the cell surface in basal cells and this rises to approx. 30% in the
presence of insulin (Fig. 1B). The ﬁgure in the basal state is likely to be
an over-estimate as the method we use in the calculation cannot easily
discriminate between Rip11 in the plasma membrane itself, and
that present in vesicles that immediately underlie the membrane (i.e.
docked vesicles).
As shown in Fig. 1B, the insulin-stimulated translocation of GFP-
tagged Rip11 to the plasma membrane was blocked by PIK-75, a small
molecule p110α-selective PI 3-kinase inhibitor [28]. This occurred in
parallel with an inhibition of Akt phosphorylation on serine 473
(Fig. 1C), an event well established to be regulated by Class I PI 3-
kinase isoforms. By contrast, MK2206, a highly selective allosteric Akt
inhibitor, had no effect on insulin-stimulated GFP–Rip11 translocation
(Fig. 1B) despite almost completely inhibitingAkt Ser-473 phosphoryla-
tion (Fig. 1C). This data suggests that the ability of insulin to stimulate
Rip11 translocation to the plasma membrane is dependent on the
p110α class of PI 3-kinase but independent of the activation of the
downstream kinase Akt.Fig. 2. Insulin does not alter the rate of Rip11 vesicle fusion with the plasma membrane.
3T3–L1 adipocytes electroporated with plasmids encoding GFP–Rip11 or HA–GLUT4–
GFP were serum starved and stimulated with or without insulin (87 nM) as indicated.
(A) Cells were imaged live by TIRF microscopy at 2 frames/s using a penetration depth
of 90 nm. Scale bar represents 1 μm. (B) The rate of vesicle fusion was calculated per
μm2 membrane area per second. The graph represents mean ± SEM (N= 3, n = 8–343
fusion events, **p b 0.01, t-test, or not signiﬁcant, ns).
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plasma membrane
To explore the trafﬁcking route by which Rip11 translocates to the
plasma membrane in response to insulin we used total-internal reﬂec-
tion ﬂuorescence (TIRF) microscopy. This technique, as deployed in
our experiments, allows us tomonitor the behaviour of any intracellular
vesicles found within 90 nm of the plasma membrane and also any
ensuing fusion events occurring between these two membranous
compartments.
In these experiments we found numerous highly dynamic GFP–
Rip11 decorated vesicles in the region underlying the plasma mem-
brane and thus within the TIRF zone. A sub-fraction of these vesicles
underwent transient attachment to the plasma membrane prior to a
rapid diffusion of theﬂuorescence away from the central point of vesicle
attachment and into the membrane leaﬂet. The characteristics of these
fusion events (Fig. 2A, top panels) were very similar to those of GFP-
tagged GLUT4 vesicles that we, and others [29,30], have demonstrated
to undergo direct fusion with the plasma membrane leaﬂet (see
Fig. 2A, lower panels).
In the basal state the fusion rate was calculated to be 1.09 ±
0.18 × 10−4 events/μm2/s. This rate is similar to fusion rates observed
for other recycling endosomal proteins, for example the transferrin
receptor which exhibits 1.7 × 10−4 fusion events/μm2/s in non-
stimulated 3T3–L1 adipocytes [31], but almost three times higher than
the basal fusion rate obtained for GLUT4 vesicles in these cells
(0.40 ± 0.20 × 10−4 events/μm2/s). The rate of GFP–Rip11 fusion wasFig. 3. Rip11 vesicles fusing with the plasma membrane are positive for Rab11, but devoid of GL
and HA–GLUT4–GFP) (panels A and B), or GFP-Rip11 and mCherry.Rab11 (panel C) were stimu
panel (D) Rip11 fusion events were identiﬁed manually from images and examined for the p
mean± SEM from three separate experiments (N= 3), inwhich 67–132 vesicles (‘n’) were exa
and Rab4 vesicle fusion rates.unchanged upon insulin stimulation, which contrasts with the more
substantial increase in the rate of fusion of GLUT4 vesicles in response
to insulin (Fig. 2B).
The data suggest that insulin does not stimulate an increase in
the amount of GFP–Rip11 at the plasma membrane via its ability to
co-trafﬁc with (or ‘piggy back’ on) insulin-regulated GLUT4 vesicles.
This was conﬁrmed using two-colour TIRF in which we imaged GFP–
GLUT4 and a mCherry-tagged Rip11, which were co-expressed in the
same 3T3–L1 adipocyte. In these experiments the majority of GLUT4
vesicles that we observed fusing with the plasma membrane were de-
void of Rip11 (Fig. 3A). Similarly, the majority of fusing Rip11 vesicles
were negative for GLUT4 (Fig. 3B and quantiﬁcation in Fig. 3D), as
well as IRAP, the transferrin receptor and Rab4 (Fig. 3D). By contrast,
52.6 ± 3.7% of the Rip11 fusing vesicles were positive for the known
Rip11-binding partner, Rab11 (Fig. 3C and D).
The data suggest that Rip11 and GLUT4 trafﬁc to the plasma
membrane via distinct pathways, and that the effect of insulin on
GFP–Rip11 translocation does not involve an increase in the rate of
vesicle exocytosis or fusion with the plasma membrane.
3.3. Rip11 translocation does not require an interaction between its C2
domain and phosphoinositide lipids
Rip11 is found associatedwith intracellular vesicles, as well as in the
cytosolic fraction of cells [16]. Rip11 also possesses a C2 domain that has
been previously shown to bind to phosphoinositides, including
PI(3,4,5)P3, and phosphatidic acid [14]. Furthermore, this domain hasUT4 and IRAP. 3T3–L1 adipocytes electroporated with plasmids encodingmCherry–Rip11
lated with 87 nM insulin and examined by TIRF microscopy. Scale bar represents 1 μm. In
resence of ﬂuorescently-tagged GLUT4, IRAP, TfnR, Rab4 or Rab11. The graph represents
mined from 4 to 5 cells per experiment. *p b 0.05 versus GLUT4, IRAP, transferrin receptor
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translocation of Rip11. The levels of PI(3,4,5)P3 are rapidly and substan-
tially increased by insulin in the plasma membrane of 3T3–L1 adipo-
cytes [32]. We asked, therefore, whether the interaction of Rip11 with
PI(3,4,5)P3 was required for Rip11 translocation, perhaps via binding
of a soluble pool of the protein to plasma membrane derived
PI(3,4,5)P3 using a mechanism similar to that deployed by Akt, which
possesses a PI(3,4,5)P3-binding Pleckstrin Homology (PH) domain [32].
We ﬁrst sought to produce a mutant Rip11 that could not bind
PI(3,4,5)P3. To do thiswe searched for basic residues in the Rip11 C2 do-
main thatmight be involved in phosphoinositide binding, by generating
a homology model based on the published phosphoinositide-binding
PKCα C2 domain structure [33]. Our model (VJJ & JMT, unpublished
data) suggested that the Rip11 C2 domain residues most likely to be in-
volved in PI(3,4,5)P3-binding were the surface-associated arginine-52
and lysine-54 (numbering according to NCBI NP_056285.1; Fig. 4A).
Recombinantwild-type Rip11 C2 domain (‘WT’; amino acids 2–221)
and an equivalent C2 domain R52A/K54Amutant (‘PI’) were cloned and
fused to GST for expression in, and puriﬁcation from, E. coli. The ability
of the puriﬁed recombinant proteins to bind phosphoinositide lipids
was studied using a protein–lipid overlay assay as previously described
[14]. As shown in Fig. 4B, the wild-type Rip11 C2 domain bound
to PtdIns(4,5)P2 and PtdIns(3,4,5)P3, and to a lesser extent to
PtdIns(3,5)P2. No binding was detected to PtdIns(3,4)P2. Strikingly,
the R52A/K54A mutations (Rip11 ‘PI’ mutant) almost completely
inhibited phosphoinositide-binding (Fig. 4B).
As the Rip11 C2 domain has also been shown to bind to the neutral
phospholipids phosphatidylcholine (PC) and phosphatidylethanol-
amine (PE) [16], we wanted next to investigate the effect of the muta-
tions on the binding to these lipids. In order to do so, we used a
liposome binding assay, in which PC:PE liposomes (80:20) were
incubated with puriﬁed recombinant proteins (Rip11 C2 domain, WT
or the PI mutant). After sedimentation by centrifugation, boundFig. 4. Identiﬁcation of a surface phosphoinositide binding patchonRip11 (A) Schematic diagram
C2 domain mutant (the ‘PI’mutant) which was incapable of binding to phosphoinositide lipids
alonewere incubatedwith PIP Strips™. Bound proteinswere detected by blotting themembran
were incubatedwith phosphatidylcholine/phosphatidyl-ethanolamine (80:20) liposomes for 3
and resolved by SDS-PAGE before detection using an HRP-coupled anti-GST antibody. The grapproteins were analysed by Western blotting. As shown in Fig. 4C, bind-
ing to neutral liposomes was unaffected by the mutations. Taken
together the results strongly suggest that basic residues R52 and K54
form a surface patch that is selectively involved in phosphoinositide-
binding by the Rip11 C2 domain.
We next analysed the effect of themutations on the translocation of
GFP–Rip11 to the plasma membrane in response to insulin in 3T3–L1
adipocytes. In the basal state, wild-type GFP–Rip11 and the GFP–
Rip11–PI mutant localised to the perinuclear region of the cell and to
peripheral vesicles, but were largely excluded from the plasma
membrane (Fig. 5A) suggesting that phosphoinositide-binding is
not necessary for Rip11 targeting to intracellular membranes. After
insulin stimulation, we found that the GFP–Rip11–PI mutant accu-
mulated at the plasma membrane in a manner indistinguishable
from the wild-type protein (Fig. 5A and B). The data suggest that
phosphoinositide-binding is not required for Rip11 translocation to
the plasma membrane.
3.4. Inhibition of dynamin function mimics insulin-stimulated Rip11
translocation
The studies above suggest that insulin does not stimulate Rip11
translocation to the plasmamembrane via the binding of Rip11 to plas-
ma membrane derived phosphoinositide lipids such as PI(3,4,5)P3 or
through an increase in the rate of Rip11 vesicle exocytosis. Given that
insulin has been reported to inhibit GLUT4 endocytosis in adipocytes
[34,35] we next asked whether an inhibition of Rip11 endocytosis by
insulin might be the underlying cause of the apparent translocation
we observe.
To explore this, we used the dynamin inhibitor Mitmab. Dynamin
plays a key role in both clathrin- [36] and caveolin-dependent [37]
endocytosis of cargo, including, for example, the transferrin receptor.
As shown in Fig. 6A, and as quantiﬁed in Fig. 6B, Mitmab mimickedof Rip11 highlighting residuesR52 andK54whichweremutated to alanines to generate a
. (B) Recombinant GST–Rip11 C2 domain (amino acids 2–221; ‘WT’ or ‘PI’mutant) or GST
ewith an HRP-coupled anti-GST antibody. (C) The indicated puriﬁed recombinant proteins
0min at room temperature. Bound recombinant proteins were solubilised in sample buffer
h represents mean ± SEM (N = 3).
Fig. 5. Phosphoinositide binding is not required for Rip11 translocation to the cell surface
in response to insulin stimulation. 3T3–L1 adipocytes stably expressing GFP–Rip11 (WT or
the PImutant)were serum starved and stimulatedwith orwithout insulin before ﬁxation.
(A) Shows images of the cells treated in the absence or presence of insulin, as indicated,
obtained by confocal microscopy. Scale bar represents 10 μm. (B) The graph represents
mean ± SEM of the amount of Rip11 at the cell surface normalised to total Rip11 expres-
sion. (N = 3, n = 30 cells). *p b 0.05, t-test.
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membrane, while at the same time it almost completely blocked the
uptake of ﬂuorescent transferrin (Fig. 6A), as expected. Importantly,
the inactive analogue of Mitmab (pro-myristic acid) was without effect
on GFP–Rip11 translocation (Fig. 6B). To further conﬁrm the speciﬁcity
of the effect, we used Dynole-34-2, a structurally dissimilar inhibitor of
dynamin-dependent endocytosis and its inactive analogue Dynole 31–2
[38]. Again, Dynole 34–2 almost completely mimicked the effect of
insulin, while its inactive analogue was without effect (Fig. 6B).
Taken together the data suggest that insulin promotes GFP–Rip11
accumulation in the plasma membrane through an inhibition of
endocytosis, rather than by stimulating GFP–Rip11 vesicle exocytosis.
Interestingly, we had noted that nocodazole, which inhibits vesicle
exocytosis by promoting the depolymerisation of microtubules, blocks
the effect of insulin on Rip11 accumulation in the plasma membrane
(Fig. 6C). This is consistent with the requirement for continuous GFP–
Rip11 recycling for insulin to have any effect.
3.5. Insulin inhibits Rip11 endocytosis in a PI 3-kinase-dependent and
Akt-independent manner
To conﬁrm that insulin directly affects Rip11 endocytosis, we per-
formed a ‘Mitmab washout’ experiment, taking advantage of the fact
that Mitmab is a reversible dynamin inhibitor [36]. Cells were ﬁrstincubated with Mitmab to promote the accumulation of GFP–Rip11 in
the plasma membrane. The cells were then washed to remove the
Mitmab (t = 0 in Fig. 7A), before continuing the incubation in the ab-
sence or presence of insulin. Cells were ﬁxed at 5, 15 and 30 min and
the rate at which GFP–Rip11 re-internalised was measured. We rea-
soned that if insulin inhibited GFP–Rip11 endocytosis, then the rate at
which GFP–Rip11 is removed from the plasma membrane should be
slowed. As shown in Fig. 7A, we did indeed observe that the level of
plasma membrane associated GFP–Rip11 fell in the absence of insulin
and that this fall was slowed in its presence.
As the insulin-stimulated accumulation of GFP–Rip11 in the plasma
membrane was shown to be PI 3-kinase dependent but independent of
Akt activity (Fig. 1B), we next wanted to conﬁrm that this was also the
case for the ability of insulin to inhibit GFP–Rip11 endocytosis. Cells
were incubated in Mitmab to promote an increased level of cell surface
GFP–Rip11 andwashed to then remove theMitmab. The cellswere then
further incubated in the presence of insulin, but with or without
the addition of MK2206 or PIK-75. As shown in Fig. 7B, the ability
of insulin to slow GFP–Rip11 endocytosis was completely prevented
by the PI 3-kinase inhibitor, PIK-75. By contrast, the Akt inhibitor
MK2206 was without effect. These collective observations are consis-
tent with the data shown in Fig. 1B.
4. Discussion
It is well established that Rip11 plays an important role in regulating
the trafﬁcking of cargo between early endosomes and recycling
endosomes [15], and between the endosomal recycling compartment
and the plasma membrane [14,16]. Rip11 has also been demonstrated
to translocate from an intracellular compartment(s) to the plasma
membrane in response to insulin and phorbol esters [14,21], and in
this study we have explored the mechanism of this effect of insulin in
greater detail using the 3T3–L1 adipocyte model system.
We initially reasoned that the stimulus-induced increase in abun-
dance of Rip11 at the plasmamembrane could occur through enhanced
delivery of Rip11 on exocytic vesicle carriers, in particular those also
containing the insulin-regulated GLUT4 glucose transporter. The rate
of Rip11 vesicle fusion with the plasma membrane was measured
using TIRF microscopy, but this was unchanged in response to insulin
(Fig. 2B), unlike the increased fusion of the insulin-regulated cargo,
GLUT4. This strongly suggests that the movement of Rip11 towards
the cell surface on membrane carriers is unaffected by insulin, and
that Rip11 does not translocate to the plasma membrane by ‘piggy-
backing’ on GLUT4 vesicles.
We further considered a role for the binding of a soluble cytosolic
pool of Rip11 with the plasma membrane via its phospholipid binding
C2 domain. Using molecular modelling, we identiﬁed a putative
phosphoinositide-binding patch on the surface of the Rip11 C2 domain
and which comprised the basic amino acids arginine-52 and lysine-54.
A Rip11–R52A/K54A mutant (the ‘PI’ mutant) was unable to bind
phosphoinositides lipids (Fig. 4B) but could translocate to the plasma
membrane in response to insulin in a manner indistinguishable from
the wild-type protein (Fig. 5). This makes it unlikely that insulin brings
about the translocation of Rip11 via a ﬂuid phase movement of soluble
GFP–Rip11 to the plasma membrane where it might bind, for example,
PI(3,4,5)P3 produced in response to insulin (as occurs with insulin-
stimulated Akt translocation). This contrasts with phorbol ester-
stimulated Rip11 translocation which occurs in a manner that can be
prevented by deletion of the C2 domain [14].
We then exploredwhether dynamin-mediated endocytosis played a
role in Rip11 internalisation through the use of two structurally dissim-
ilar cell-permeant small molecule dynamin inhibitors, Mitmab and
Dynole 34-2.Mitmab andDynole 34-2 bothmimicked the effect of insu-
lin on GFP–Rip11 translocation (Fig. 6A and B), while their inactive
structurally related analogues were without effect. A subsequent
‘Mitmab-washout’ experiment conﬁrmed that insulin inhibited the
Fig. 6. Inhibition of dynamin-dependent endocytosis induces Rip11 accumulation at the plasmamembrane. 3T3–L1 adipocytes expressing GFP–Rip11were serum starved and stimulated
with the following compounds: 40 μMMitmab, 40 μM pro-Myristic acid, 10 μM Dynole 34–2, 10 μM Dynole 31–2 or 10 μM nocodazole, in the presence or absence of 87 nM insulin, as
indicated. (A) Cells were labelled with ﬂuorescently-tagged transferrin (25 μg/ml) for 30min in the presence and absence of insulin orMitmab, ﬁxed and imaged by confocalmicroscopy.
Scale bar represents 10 μm. (B) Quantiﬁcation of amount of Rip11 at the cell surface in the presence or absence of dynamin inhibitors as indicated. (C) Cells were incubatedwith orwithout
nocodazole (Nz) for 30 min followed by stimulation with or without insulin in the continuous presence of nocodazole before ﬁxation and immunostaining. The histogram represent
mean ± SEM (N = 3, n = 20 cells) with *p b 0.05, **p b 0.01, (t-test).
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that nocodazole inhibited the insulin dependent appearance of GFP–
Rip11 at the plasma membrane (Fig. 6C), we propose a model in
which, in the basal state, the relatively high rate of recycling of GFP–
Rip11 maintains a continuous ﬂow of Rip11 arriving at the plasma
membrane from recycling Rab11-positive endosomes, which is
matched by a continuous re-internalisation of GFP–Rip11 from the
plasma membrane in a manner that requires dynamin. This provides
for a steady state situationwhere themajority of theGFP–Rip11 is locat-
ed in juxtanuclear recycling endosomes and only a relatively small
proportion (approx. 20% according to Fig. 1B) is found at or near the
plasmamembrane. We suggest, therefore, that insulin signalling causes
the inhibition of GFP–Rip11 internalisation through suppression of a
dynamin-dependent process, which results in a net accumulation of
Rip11 at the plasma membrane.TheprecisemechanismbywhichRip11 internalises from the plasma
membrane requires further investigation. It could occur via its direct
recruitment onto endocytic carriers, which are generated through the
action of dynamin. Alternatively, Rip11 could be indirectly recycled be-
tween the cell interior and plasmamembrane by virtue of its interaction
with a binding partner that is itself the recycled cargo. We believe it
unlikely that this binding partner is either of Rab11 or Rab14, which
are the only known Rip11 interacting Rab proteins because: (i) GFP–
Rab11 and GFP–Rab14 do not translocate to the plasma membrane of
3T3–L1 adipocytes in response to insulin (F.B., S.E.R. & J.M.T., unpub-
lished observations) and (ii) a Rip11[I630E] mutant, which cannot
bind either Rab11 or Rab14 [39], still exhibited a pronounced transloca-
tion to the plasma membrane in response to insulin [21].
Interestingly, Rip11 internalisation shares several characteristics of
the insulin-regulated cargo, GLUT4. The translocation of GLUT4 to the
Fig. 7. Insulin inhibits internalisation of Rip11 from the cell surface in a PI 3-kinase depen-
dentmanner. 3T3–L1 adipocytes stably expressing GFP–Rip11were serumstarved and in-
cubated with 40 μMMitmab for 30 min. In (A) the cells were washed in ice-cold PBS to
remove Mitmab and then incubated at 37 °C for the indicated times in the continuous
presence (squares) or absence (diamonds) of insulin. The amount of cell surface Rip11
was quantiﬁed from the images obtained by confocal microscopy. In (B) the cells were
washed in ice-cold PBS and then incubated at 37 °C for 30 min in the absence (basal) or
continuous presence of insulin, MK2206 or PIK-75, as indicated. The histogram represents
mean ± SEM (N = 2, n = 25 cells).
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increase in the trafﬁcking of the transporter from a specialised GLUT4
storage compartment, however the hormone has also been shown to
have an inhibitory effect on GLUT4 endocytosis, particularly in adipo-
cytes [34,40–44]. The inhibition of GLUT4 internalisation by insulin is
PI 3-kinase dependent but Akt-independent [42,45]. Furthermore,
GLUT4 internalisation occurs at least in part via a dynamin-dependent
pathway in adipocytes and muscle cells [46–48]. This suggests that
Rip11 internalisation could indeed occur by co-trafﬁcking with GLUT4
on endocytic carriers. We were unable to observe GLUT4 endocytosis
using TIRF microscopy, so this possibility requires further future
investigation.
It is well established that Rip11 plays a central role in directing the
trafﬁcking of cargo between endosomes and recycling endosomes [15]
and between endosomal compartments and the plasma membrane
[14,16], so the reason why Rip11 accumulates at the plasmamembrane
in response to stimuli such as insulin and phorbol esters is poorly under-
stood. In polarisedMDCK cells Rip11 has been reported to be important
for trafﬁcking IgA from supranuclear apical recycling endosomes to the
plasmamembrane through amechanism likely to involve Rab11 [16]. In
adipocytes, we have reported that Rip11 plays a role as a scaffolding
protein in the fusion of intracellular GLUT4 vesicles with the plasma
membrane [21], rather than in their translocation from intracellular
compartments. An insulin-dependent accumulation of Rip11 in the
plasma membrane as a result of an inhibition of dynamin-dependentRip11 endocytosis, could bring Rip11 into juxtaposition with fusing
GLUT4 vesicles whereby it then controls the fusion process.
To conclude, our current study demonstrates that insulin promotes
Rip11 translocation to the plasma membrane via a dynamin- and PI 3-
kinase-dependent, but Akt-independent, route. Given the similarities
between the mechanism of insulin-regulated GLUT4 endocytosis,
about which relatively little is known, and that of Rip11, further studies
of these related phenomena are clearly warranted.
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